Diligence memo · auto-generated · as of July 2, 2026
Aniluxx Biotechnology, Inc.
Aniluxx Biotechnology, Inc. has raised $200K over 1 round; too few niche peers to rank its valuation yet.
Businessfiled
Aniluxx Biotechnology, Inc. operates in Biotech, based in CHAPEL HILL.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Aniluxx Biotechnology, Inc. has raised $200K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $200K on 2019-12-09.
Most recent recorded round closed around 2019-12-09.
Valuation (modeled)modeled
Provath models Aniluxx Biotechnology, Inc. at approximately $11M (range $107K–$125M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Last raise 6.6 yr ago; this sector typically re-raises about every 11 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 68% of Biotech peers (233 compared).
Modeled value ranks above 74% of those peers.
Closest niche peers: Exponential Genomics Inc., CMTx Biotech, Inc., Empire Genomics Corp..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.